S-1/A: Calidi Biotherapeutics Files Amendment for Potential Stock Issuance and Resale

Calidi Biotherapeutics files an amendment to its registration statement related to the issuance of common stock upon warrant exercises and resale by selling securityholders.

Summary

• Calidi Biotherapeutics has filed an amendment to its Form S-1 registration statement.
• The filing pertains to the potential issuance of up to 11,500,000 shares of common stock upon the exercise of public warrants.
• It also covers the offer and sale of up to 23,301,960 shares of common stock by selling securityholders.
• These shares include those from registration rights agreements, debt obligation cancellations, forward purchase agreements, and private placement warrants.
• The company's common stock and public warrants are listed on the NYSE American under the symbols CLDI and CLDI WS, respectively.
• As of January 5, 2024, there were 35,492,403 shares of common stock outstanding.
• The closing price on January 5, 2024, was $1.46 per share and $0.024 per warrant.
• The company is currently an emerging growth company and a smaller reporting company.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it outlines the potential for future growth and capital raising, it also highlights significant risks and uncertainties, including the company's history of losses and the need for additional funding.

Positives

• The registration statement allows for the potential raising of capital through the exercise of warrants.
• The registration statement provides liquidity for existing securityholders through the resale of their shares.

Negatives

• The exercise price of the warrants ($11.50) is significantly above the current trading price ($1.46), making exercise unlikely unless the stock price increases substantially.
• The resale of a large number of shares (approximately 65.7% of outstanding shares) could significantly depress the stock price.
• The company is an emerging growth company and a smaller reporting company, which may indicate a higher risk profile.

Risks

• The exercise price of the warrants is significantly above the current trading price.
• The resale of a large number of shares could significantly depress the stock price.
• The company's market is thinly traded which may adversely affect the liquidity and price of our securities.
• The price of our stock may be volatile, which could result in substantial losses for investors.
• If we fail to comply with the continued listing standards of the NYSE American, our common stock could be delisted.
• The Sponsor, Metric, anchor investors and other investors purchased or received as an inducement to facilitate the Business Combination the Sponsor Shares that were acquired by the Sponsor, Metric or anchor investors at $0.004 per share price which is significantly below the current market price of a share of our common stock and such holder could sell their shares and generate a significant profit while causing the trading price of our common stock to decline significantly.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical trials and seeks regulatory approval.

Industry Context

The document relates to the biopharmaceutical industry, specifically companies developing immuno-oncology therapies for cancer. It mentions competition from major pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• The document mentions several companies developing viral immunotherapies, including Oncorus, Replimune, Amgen, Immavir, Fergene and IconOVir.
• It also references the first viral immunotherapy, talimogene laherparepvec (Imlygic, Amgen), which has received FDA approval.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity securities.
• The resale of a large number of shares could depress the stock price, negatively impacting shareholders.
• The company's ability to execute its business plan and develop new therapies depends on securing sufficient funding.

Next Steps

• The selling securityholders may offer, sell, or distribute the securities registered in the prospectus.
• The company may receive proceeds from the exercise of warrants for cash.
• The company will need to raise additional capital through the issuance of equity or debt securities.

Key Dates

Keywords

common stock, warrants, resale, registration statement, selling securityholders, Calidi Biotherapeutics, exercise price, emerging growth company, smaller reporting company, First Light Acquisition Group, Business Combination